Monitoring chronic cough: current and future techniques

Smith, Jaclyn A.

doi:10.1586/ers.10.63

Cited by 21 publications

(13 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The choice of comparator, whether inert placebo or active, depends on the incidence and severity of drug side-effects. For proof of concept studies, the primary outcome measure should be objective, and cough frequency monitors are the ideal tool Smith, 2010a;Barton et al, 2012). However, given the large placebo response reported in many clinical trials evaluating cough (Eccles, 2006), a placebo arm would seem to be vital in determining the likely antitussive action of any drugnew or old.…”

Section: Clinical Trial Design For Evaluation Of Antitussive Drugsmentioning

confidence: 99%

Antitussive Drugs—Past, Present, and Future

et al. 2014

View full text Add to dashboard Cite

Section: Clinical Trial Design For Evaluation Of Antitussive Drugsmentioning

confidence: 99%

Antitussive Drugs—Past, Present, and Future

et al. 2014

View full text Add to dashboard Cite

“…Yet, there are numerous challenges in recording, analysing and quantifying cough sounds and current systems have only been tested over short time periods and in limited patient groups [47].…”

Section: Measuring Sleep Disturbances In Copdmentioning

confidence: 99%

Night-time symptoms: a forgotten dimension of COPD

Agustí¹,

Hedner²,

Marı́n³

et al. 2011

Eur Respir Rev

205

189

View full text Add to dashboard Cite

Sleep quality is often poor in patients with chronic obstructive pulmonary disease (COPD), but these night-time symptoms are frequently unnoticed by physicians and/or not reported by patients themselves. Therefore, the prevalence and clinical impact of sleep disturbances and night-time symptoms in COPD is not well understood and has not been a clinical focus to date. To address this gap, an expert panel meeting was convened in Barcelona, Spain, in March 2011 to discuss the aetiology, evolution, burden, long-term clinical consequences and optimal management of night-time symptoms in COPD. The term ''night-time symptoms'' in COPD has not been distinctly defined in an objective sense but epidemiological data suggests that the prevalence of nocturnal symptoms and symptomatic sleep disturbance may exceed 75% in patients with COPD. The panel concluded that night-time symptoms in COPD are prevalent and bothersome; that their cause(s) are multiple and include demographic factors, such as age and obesity, pharmacotherapy, disease-specific symptoms and the presence of comorbid sleep disorders, and other medical conditions; and that potential long-term consequences can include lung function changes, increased exacerbation frequency, emergence or worsening of cardiovascular disease, cognitive effects, depression, impaired quality of life and increased mortality. To date, few interventional studies have investigated them, but emerging data suggest that bronchodilator therapy can improve them if deployed appropriately. In summary, night-time symptoms in COPD warrant further clinical investigation with validated tools.

show abstract

“…This is a more representative measure of the symptom of cough, as it does not rely upon patient recall and is carried out in the patient's natural environment, rather than under laboratory conditions (Smith 2010). Patients wear a discrete recording device equipped with a microphone which records cough sounds over a set time period Smith 2010).…”

Section: Ambulatory Cough Countingmentioning

confidence: 99%

“…There are currently several systems in use, but none are commercially available at present; the LifeShirt (VivoMetrics Incorporate, Ventura, CA) (Coyle et al 2005;Smith 2010) and the CoughCOUNT (KarmelSonix, Haifa, Israel) (Vizel et al 2010) are no longer in production. The other systems in use include the Leicester Cough Monitor, which, although widely published, is not yet fully automated ) (McGuinness et al 2008.…”

Section: Ambulatory Cough Countingmentioning

confidence: 99%

“…The final cough counting system is the VitaloJAK (Vitalograph Limited, Buckinghamshire, UK), which uses a custom-made digital recording device to record cough through sounds detected by microphones on the chest wall and lapel ). This monitoring system no longer requires calibration (Smith 2010) and consists of a compression algorithm that removes silence and the bulk of non-cough sounds from 24-h acoustic recordings. This provides a sound file an average of 85 min in length containing median 100.0 % (range 97.3-100 %) of coughs in the original 24-h recording when tested on a group of 47 subjects, including chronic cough, asthma, COPD, lung cancer and healthy controls (McGuinness et al 2012 and unpublished data).…”

Section: Ambulatory Cough Countingmentioning

confidence: 99%

See 1 more Smart Citation

Targeting TRP channels for chronic cough: from bench to bedside

Bonvini

Birrell

Smith

et al. 2015

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Cough is currently the most common reason for patients to visit a primary care physician in the UK, yet it remains an unmet medical need. Current therapies have limited efficacy or have potentially dangerous side effects. Under normal circumstances, cough is a protective reflex to clear the lungs of harmful particles; however, in disease, cough can become excessive, dramatically impacting patients' lives. In many cases, this condition is linked to inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD), but can also be refractory to treatment and idiopathic in nature. Therefore, there is an urgent need to develop therapies, and targeting the sensory afferent arm of the reflex which initiates the cough reflex may uncover novel therapeutic targets. The cough reflex is initiated following activation of ion channels present on vagal sensory afferents. These ion channels include the transient receptor potential (TRP) family of cation-selective ion channels which act as cellular sensors and respond to changes in the external environment. Many direct activators of TRP channels, including arachidonic acid derivatives, a lowered airway pH, changes in temperature, and altered airway osmolarity are present in the diseased airway where responses to challenge agents which activate airway sensory nerve activity are known to be enhanced. Furthermore, the expression of some TRP channels is increased in airway disease. Together, this makes them promising targets for the treatment of chronic cough. This review will cover the current understanding of the role of the TRP family of ion channels in the activation of airway sensory nerves and cough, focusing on four members, transient receptor potential vanilloid (TRPV) 1, transient receptor potential ankyrin (TRPA) 1, TRPV4, and transient receptor potential melastatin (TRPM) 8 as these represent the channels where most information has been gathered with relevance to the airways. We will describe recent data and highlight the possible therapeutic utility of specific TRP channel antagonists as antitussives in the clinic.

show abstract

Monitoring chronic cough: current and future techniques

Cited by 21 publications

References 49 publications

Antitussive Drugs—Past, Present, and Future

Antitussive Drugs—Past, Present, and Future

Night-time symptoms: a forgotten dimension of COPD

Targeting TRP channels for chronic cough: from bench to bedside

Contact Info

Product

Resources

About